LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
How can edtech startups tell if their products work? LEANLAB partners research tech use in real KC classrooms
A rebooted accelerator concept for LEANLAB Education put four edtech companies into Kansas City classrooms this spring — focusing more on helping founders conduct research on their products inside of schools and de-emphasizing previous entrepreneur training aspects of LEANLAB’s programming. “As the first program of its kind in the U.S., this inaugural cohort represents a turning…
Stackify sells to West Coast competitor; stacking another exit for startup veteran Matt Watson
Two of the country’s fastest growing companies have joined forces as Leawood-built Stackify reaches its exit, the tech startup announced Tuesday. Huntington Beach, California-based Netreo has acquired the company in an undisclosed deal, expected to enhance the IT infrastructure management (ITIM) platform’s full-stack IT monitoring and AIOps offerings — significantly boosting its overall customer experience. …
SnapIT sees 100 percent jump in female tech students; builds on ‘Future of Work’ summit
As the job market shifts in a post-pandemic world, an Overland Park company reports virtual training options and changes in coastal employer mindsets have opened access for women in tech like never before. “COVID created a situation where working from home has become a long-term solution, leading to more opportunities for the Midwest [talent overall],”…
‘Not an over-glorified hobby’: Comic book creator designs app to help vendors find conventions, sketch path to profitability
Juaquan Herron spent countless hours actively searching for comic conventions to share and sell his work — often feeling frustrated after learning about conventions too late, he recalled. “Especially starting out in the industry, I didn’t have many friends and wasn’t finding out about vending opportunities,” said Herron, who founded 2923 Comics and created the…